Humacyte FDA Approval of Treatment of Extremity Vascular Trauma

 – SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –

– In clinical testing SYMVESS was observed to have high rates of patency, or blood flow,
and low rates of amputation and infection –

– Highly experienced sales team already recruited and trained in preparation for commercial launch –

https://www.globenewswire.com/news-release/2024/12/20/3000367/0/en/Humacyte-Announces-FDA-Approval-of-SYMVESS-acellular-tissue-engineered-vessel-tyod-for-the-Treatment-of-Extremity-Vascular-Trauma.html